Highlights

  • Cochlear expects low single-digit constant-currency Revenue growth in FY27, with underlying net profit guided to $330 million to $350 million.
  • The Nucleus Nexa System, which represented more than 95% of implant sales in developed markets by June, is central to the company’s product-led growth strategy.
  • Management has freed up an additional $25 million of growth Investment in FY27 by reducing fixed costs, aimed at referral programs and digital candidate tools.
  • Improving adult referral pathways in the US — where medical referrals currently account for only 40% of adult implant referrals — is a specific area of focus.

Cochlear (ASX:COH) is heading into FY27 with its growth strategy increasingly anchored to two things: the continued rollout of its Nucleus Nexa System and a push to fix long-standing gaps in how adult patients get referred for cochlear implants in the US. Both will be important in determining whether the company can lift Underlying Profit back toward its medium-term Margin target.

Nexa Adoption Sets Up the Next Product Cycle

The Nucleus Nexa System, described by Cochlear as the first smart cochlear implant system with upgradeable firmware, had already reached more than 95% of implant sales across developed markets by June, alongside an average 3% price increase. Management is using Nexa as the platform for further development, including a drug-eluting electrode and a totally implantable cochlear implant — initiatives that, if successful, would extend Cochlear’s product differentiation well beyond FY27.

Referral Pathways Are a Specific Growth Lever

A recurring theme in Cochlear’s outlook is the gap between the number of people who could benefit from a cochlear implant and the number who are actually referred. Medical and professional referrals currently account for just 40% of adult cochlear implant referrals in the US, and the company is expanding initiatives to make referral activity more systematic and to lift medical engagement — a lever management sees as key to lifting implant volumes without relying purely on pricing.

Cost Discipline Frees Up Growth Investment

Cochlear has reduced fixed costs to create capacity for an additional $25 million of growth investment in FY27, to be directed toward referral programs, digital candidate tools, clinical workflow improvements and payer evidence generation. That reallocation, rather than higher overall spending, is the mechanism management is using to fund growth initiatives while working to protect margins.

Margin Recovery Remains a Multi-Year Task

FY26’s net profit margin of 14% remains well below the company’s medium-term target of 18%, weighed down by a higher mix of lower-priced emerging-market implant units, transitional restructuring costs and foreign exchange movements. FY27 guidance of low single-digit constant-currency revenue growth and underlying net profit of $330–$350 million assumes gradual improvement in developed-market implant performance rather than a rapid margin recovery.

What to Watch

Key markers for the year ahead include the pace of further Nexa-related product development, whether US referral initiatives begin lifting implant volumes, and whether developed-market performance — particularly in the US and Western Europe — stabilises after a mixed FY26 across regions.

Conclusion

Cochlear’s near-term trajectory depends on translating rapid Nexa adoption and referral-pathway initiatives into steadier implant revenue growth, while continuing to work back toward its 18% medium-term margin target. FY27 guidance of $330–$350 million in underlying net profit reflects a gradual, rather than immediate, recovery path.